Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-fluoro substitution prevents quinoid formation

Chemical Research in Toxicology

Volumn 18, Issue 2, 2005, Pages 162-173

  Liu, Hong ^a   Liu, Ju ^a   Van Breemen, Richard B ^a   Thatcher, Gregory R J ^a   Bolton, Judy L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' FLUORONORARZOXIFENE; ALKALINE PHOSPHATASE; ARZOXIFENE; DEOXYNUCLEOSIDE; DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; FLUORINE DERIVATIVE; GLUTATHIONE; NORARZOSIFENE DIQUINONE METHIDE GLUTATHIONE CONJUGATE; NORARZOXIFENE; NORARZOXIFENE DIQUINONE METHIDE; NORARZOXIFENE DIQUINONE METHIDE DEOXYGUANOSINE ADDUCT; NORARZOXIFENE O QUINONE GLUTATHIONE CONJUGATE; NUCLEOSIDE; QUINOID; QUINONE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIESTROGEN ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CHEMICAL MODIFICATION; CONJUGATE; DNA ADDUCT; DNA DAMAGE; DRUG ACTIVATION; DRUG ACTIVITY; DRUG METABOLISM; DRUG STRUCTURE; ENDOMETRIUM CANCER; ENZYME INDUCTION; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; ISHIKAWA CELL; LIVER MICROSOME; NONHUMAN; NORMAL HUMAN; OXIDATION REDUCTION REACTION; PH; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; RECEPTOR BINDING; SUBSTITUTION REACTION; SYNTHESIS; TEMPERATURE; TOXICOKINETICS;

ALKALINE PHOSPHATASE; ANIMALS; BIOTRANSFORMATION; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; ESTRADIOL; FEMALE; GLUTATHIONE; HUMANS; KINETICS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OLIGODEOXYRIBONUCLEOTIDES; PIPERIDINES; QUINONES; RATS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 13844269367     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx049776u     Document Type: Article

References (43)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. (1999) Cancer statistics. Ca Cancer J. Clin. 49, 8-31.
2. Osborne, C. K. (1998) Tamoxifen in the treatment of breast cancer. N. Engl J. Med. 339, 1609-1618.
3. Hortobagyi, G. N. (1998) Treatment of breast cancer. N. Engl. J. Med. 339, 974-984.
4. Barakat, R. R. (1995) The effect of tamoxifen on the endometrium. Oncology 9, 129-134; discussion 139-140, 142.
5. Bertelli, G., Pronzato, P., Amoroso, D., Cusimano, M. P., Conte, P. F., Montagna, G., Bertolini, S., and Rosso, R. (1988) Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res. Treat. 12, 307-310.
6. Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A., and Ashley, S. (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14, 78-84.
7. Henderson, B. E., Ross, R., and Bernstein, L. (1988) Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 48, 246-253.
8. Bolton, J. L. (2002) Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens. Toxicology 177, 55-65.
9. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Role of quinones in toxicology. Chem. Res. Toxicol. 13, 135-160.
10. Kim, S. Y., Suzuki, N., Laxmi, Y. R., and Shibutani, S. (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab. Rev. 36, 199-218.
11. Phillips, D. H., Potter, G. A., Horton, M. N., Hewer, A., Crofton-Sleigh, C., Jarman, M., and Venitt, S. (1994) Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15, 1487-1492.
12. Moorthy, B., Sriram, P., Pathak, D. N., Bodell, W. J., and Randerath, K. (1996) Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res. 56, 53-57.
13. Dehal, S. S., and Kupfer, D. (1996) Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res. 56, 1283-1290.
14. Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A. C., Shah, A. S., Huster, W. J., Draper, M., and Christiansen, C. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641-1647.
15. Kelminski, A. (2002) The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer. Hawaii Med. J. 61, 209-210.
16. Gradishar, W., Glusman, J., Lu, Y., Vogel, C., Cohen, F. J., and Sledge, G. W., Jr. (2000) Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88, 2047-2053.
17. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
18. Yu, L., Liu, H., Li, W., Zhang, F., Luckie, C., Van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2004) Oxidation of Raloxifene to Quinoids: Potential Toxic Pathways via a Diquinone Methide and o-Quinones. Chem. Res. Toxicol. 17, 879-888.
19. Dardes, R. C., Bentrem, D., O'Regan, R. M., Schafer, J. M., and Jordan, V. C. (2001) Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. Clin. Cancer. Res. 7, 4149-4155.
20. McMeekin, D. S., Gordon, A., Fowler, J., Melemed, A., Buller, R., Burke, T., Bloss, J., and Sabbatini, P. (2003) A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol. Oncol. 90, 64-69.
21. Baselga, J., Llombart-Cussac, A., Bellet, M., Guillem-Porta, V., Enas, N., Krejcy, K., Carrasco, E., Kayitalire, L., Kuta, M., Lluch, A., Vodvarka, P., Kerbrat, P., Namer, M., and Petruzelka, L. (2003) Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann. Oncol. 14, 1383-1390.
22. Chan, S. (2002) Arzoxifene in breast cancer. Eur. J. Cancer 38 (Suppl 6), S55-S56.
23. Suh, N., Glasebrook, A. L., Palkowitz, A. D., Bryant, H. U., Burris, L. L., Starling, J. J., Pearce, H. L., Williams, C., Peer, C., Wang, Y., and Sporn, M. B. (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 61, 8412-8415.
24. Vernon, M. W. (1990) Experimental endometriosis in laboratory animals as a research model. Prog. Clin. Biol. Res. 323, 49-60.
25. Thomas, W., Burke, M. D., and Cheryl L. Walker (2003) Arzoxifene as therapy for endometrial cancer. Gynecol. Oncol. 90, S40-S46.
26. Conzen, S. D. (2003) Current status of selective estrogen receptor modulators (SERMs). Cancer J. 9, 4-14.
27. NIH Guidlines for the Laboratory Use of Chemical Carcinogens, 1981, NIH Publication, U.S. Goverment Printing Office, Washington, DC, pp 2381-2385.
28. Palkowitz, A. D., Glasebrook, A. L., Thrasher, K. J., Hauser, K. L., Short, L. L., Phillips, D. L., Muehl, B. S., Sato, M., Shetler, P. K., Cullinan, G. J., Pell, T. R., and Bryant, H. U. (1997) Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: a novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 40, 1407-1416.
29. Curtin, D. Y., and Harder, R. J. (1960) Stereochemistry and reactions with hydroxyl ion and with silver oxide of the 2-bromo-4-phenylcyclohexanols. J. Am. Chem. Soc. 82, 2357-2368.
30. Thompson, J. A., Malkinson, A. M., Wand, M. D., Mastovich, S. L., Mead, E. W., Schullek, K. M., and Laudenschlager, W. G. (1987) Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice. Drug Metab. Dispos. 15, 833-840.
31. Iverson, S. L., Shen, L., Anlar, N., and Bolton, J. L. (1996) Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. 9, 492-499.
32. Jeng, M. H., Jiang, S. Y., and Jordan, V. C. (1994) Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER Cancer Lett. 82, 123-128.
33. Obourn, J. D., Koszewski, N. J., and Notides, A. C. (1993) Hormone- and DNA-binding mechanisms of the recombinant human estrogen receptor. Biochemistry 32, 6229-6236.
34. Liu, J., Burdette, J. E., Xu, H., Gu, C., van Breemen, R. B., Bhat, K. P., Booth, N., Constantinou, A. I., Pezzuto, J. M., Fong, H. H., Farnsworth, N. R., and Bolton, J. L. (2001) Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J. Agric. Food. Chem. 49, 2472-2479.
35. Pisha, E., and Pezzuto, J. M. (1997) Cell-based assay for the determination of estrogenic and anti-estrogenic activities. Methods Cell Sci. 19, 37-43.
36. Filar, L. J., and Winstrin, S. (1960) Preparation and behavior of simple quinone methides. Tetrahedron Lett. 25, 9-16.
37. Bolton, J. L., Comeau, E., and Vukomanovic, V. (1995) The influence of 4-alkyl substituents on the formation and reactivity of 2-methoxy-quinone methides: evidence that extended pi-conjugation dramatically stabilizes the quinone methide formed from eugenol. Chem.-Biol. Interact. 95, 279-290.
38. Dwivedy, I., Devanesan, P., Cremonesi, P., Rogan, E., and Cavalieri, E. (1992) Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem. Res. Toxicol. 5, 828-833.
39. Baillie, T. A., and Davis, M. R. (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319-325.
40. Olive, P. L., Banath, J. P., and Durand, R. E. (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat. Res. 122, 86-94.
41. Albert, J. L., Sundstrom, S. A., and Lyttle, C. R. (1990) Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line. Cancer Res. 50, 3306-3310.
42. Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W., 3rd, Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., Adrian, M. D., Cole, H. W., Magee, D. E., Phillips, D. L., Rowley, E. R., Short, L. L., Glasebrook, A. L., and Bryant, H. U. (1997) Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzo-thiophene core of raloxifene. J. Med. Chem. 40, 146-167.
43. Lee, K. C., Moon, B. S., Lee, J. H., Chung, K., Katzenellenbogen, J. A., and Chi, D. Y. (2003) Synthesis and Binding Affinities of fluoroalkylated raloxifenes. Bioorg. Med. Chem. 11, 3649-3658.